doi: 10.1073/pnas.1801609115CrossRefGoogle ScholarPubMed Nasca, C., Xenos, D., Barone, Y., Caruso, A., Scaccianoce, S., Matrisciano, F., Nicoletti, F
These include smart delivery devices, implantable systems, and targeted delivery approaches that could expand the utility of peptide therapeutics
Glp-1 (Glucagon Like Peptide) Single molecule made in the small intestine and colon Causes the pancreas to make insulin when sugar is in the blood stream, in a dose dependent fashion (the more sugar you have, the more GLP-1 tells the pancreas to release insulin) Tells the gastrointestinal tract to slow down digestion Slows down carbohydrate absorption (so your blood sugar doesnt escalate quickly) Curbs appetite Animal studies show GLP-1 may promote regeneration of the beta cells in the pancreas by fighting programmed cell death (apoptosis)
Melanotan II is not a drug, food, supplement, or cosmetic and may not be misbranded, misused, or mislabeled as a drug, food, supplement, or cosmetic